{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-114520","form_type":"8-K","ticker":"CLDX","cik":"0000744218","company_name":"Celldex Therapeutics, Inc.","filed_at":"2023-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.930026+00:00","generated_at":"2026-06-08T21:39:05.623291+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Celldex announces positive Phase 2 CSU data for barzolvolimab; $12.5M milestone triggered","bullets":["Barzolvolimab met primary endpoint: LS mean UAS7 change from baseline to week 12 was -23.87 (300mg q8w) vs -10.47 placebo (p<0.0001).","Complete control (UAS7=0) at week 12: 37.5% (300mg q8w), 51.1% (150mg q4w), 22.9% (75mg q4w) vs 6.4% placebo.","Positive Phase 2 data triggers $12.5M milestone payment under settlement agreement with SRS, to be paid in cash.","Phase 1B data in prurigo nodularis showed meaningful itch reduction and clear/almost clear skin with single 3.0 mg/kg dose."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-114520","json":"https://secwatch.observer/filing/0001104659-23-114520.json","markdown":"https://secwatch.observer/filing/0001104659-23-114520.md","text":"https://secwatch.observer/filing/0001104659-23-114520.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/744218/000110465923114520/0001104659-23-114520-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/744218/000110465923114520/tm2329928d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T21:39:05.623291+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}